| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥28.0B | ¥25.1B | +11.4% |
| Operating Income | ¥4.4B | ¥3.1B | +41.3% |
| Ordinary Income | ¥4.5B | ¥3.1B | +45.2% |
| Net Income | ¥3.0B | ¥1.8B | +69.0% |
| ROE | 9.8% | 6.5% | - |
FY2025 Q2 results: Revenue 28.0B yen (YoY +11.4%), Operating Income 4.4B yen (YoY +41.3%), Ordinary Income 4.5B yen (YoY +45.2%), Net Income 3.0B yen (YoY +69.0%). The company demonstrated robust profit expansion with operating income growth significantly outpacing revenue growth, indicating strong operating leverage. Net profit margin reached 10.7%, improving from the prior period as operating efficiency gains contributed to bottom-line acceleration. Operating cash flow of 4.5B yen remained healthy at 1.51 times net income, confirming cash-backed earnings quality. However, free cash flow turned negative at -0.4B yen due to substantial investing activities totaling -4.9B yen, primarily driven by subsidiary acquisition of -3.7B yen and capital expenditures of -1.2B yen. The company continues to operate as a single segment (veterinary hospital business) with concentrated business exposure.
Revenue increased 11.4% YoY to 28.0B yen, driven by organic growth in the veterinary hospital business and contributions from newly consolidated subsidiaries during the period. Cost of sales rose 9.9% to 20.5B yen, resulting in gross profit of 7.5B yen with gross margin improving to 26.9% from 26.4% YoY, reflecting enhanced operational efficiency. SG&A expenses were well-controlled at 3.1B yen (11.0% of revenue), declining as a percentage of sales from 12.1% in the prior period, demonstrating effective cost management and operating leverage benefits. Operating income surged 41.3% to 4.4B yen with operating margin expanding to 15.8% from 12.3% YoY, a notable 3.5 percentage point improvement.
Non-operating income and expenses netted to a small positive contribution of approximately 0.1B yen, comprising minimal interest income of 0.01B yen offset by interest expense of 0.13B yen and other minor items. Ordinary income reached 4.5B yen, advancing 45.2% YoY in line with operating performance.
Extraordinary items added 0.2B yen to pre-tax profit, including gains on asset sales of 0.08B yen, representing a non-recurring factor that boosted net income. Income tax expense of 1.7B yen resulted in an effective tax rate of approximately 36.6%. Net income of 3.0B yen grew 69.0% YoY, with the acceleration beyond operating income growth partly attributable to the extraordinary gains and tax effects.
The earnings pattern is characterized as revenue up/profit up with profit growth substantially exceeding revenue growth, driven by margin expansion through operating efficiency gains and supplemented by non-recurring gains.
The company operates a single business segment in veterinary hospital operations. Segment information disclosure is omitted due to immateriality of other segments. The veterinary hospital business represents 100% of consolidated revenue and operating income, constituting the core business with full concentration of operational and financial exposure in this sector.
[Profitability] ROE of 9.8% represents solid return on equity, supported by net profit margin of 10.7% and operating margin of 15.8%, both showing year-over-year improvement. The operating margin expansion of 3.5 percentage points reflects strong operational leverage as SG&A ratio declined despite revenue growth. Gross margin of 26.9% improved modestly from 26.4% YoY. [Cash Quality] Cash and deposits stood at 6.5B yen, declining from 8.9B yen YoY, with the reduction attributable to substantial investing activities. Operating cash flow of 4.5B yen exceeded net income by 1.51 times, confirming high-quality cash-backed earnings. Cash coverage of current liabilities at 0.49x warrants attention given liquidity positioning. [Investment Efficiency] Asset turnover of 0.448x reflects capital-intensive operations with significant intangible assets. [Financial Health] Equity ratio of 48.9% indicates moderate financial stability. Current ratio of 98.7% falls below the 100% threshold, signaling tight short-term liquidity requiring monitoring. Debt-to-equity ratio approximates 1.05x with interest-bearing debt of 18.5B yen, while interest coverage ratio remains robust at 34.03x demonstrating sufficient debt servicing capacity.
Operating cash flow of 4.5B yen represents 1.51 times net income, confirming strong cash generation quality with operating cash flow subtotal before working capital at 6.7B yen. Working capital movements were modest with inventory increase of 0.1B yen, receivables increase of 0.1B yen, and payables increase of 0.3B yen, resulting in minimal working capital impact. Income taxes paid of 2.0B yen represented a significant cash outflow. Investing cash flow of -4.9B yen was driven primarily by subsidiary acquisition of -3.7B yen and capital expenditures of -1.2B yen, with the CapEx-to-depreciation ratio of 1.28x indicating growth investments. Financing cash flow of -2.0B yen reflected debt servicing and capital structure adjustments. Free cash flow of -0.4B yen turned negative due to substantial acquisition activity, though this reflects strategic growth investments rather than operational weakness. Cash and deposits decreased 2.4B yen from 8.9B yen to 6.5B yen, with the decline driven by the large-scale subsidiary acquisition and capital investments while operating activities generated positive cash. Interest paid remained modest at 0.1B yen despite debt levels, consistent with the strong interest coverage ratio.
Ordinary income of 4.5B yen versus operating income of 4.4B yen shows minimal non-operating net contribution of approximately 0.1B yen, representing less than 1% of revenue and indicating earnings are primarily driven by core operations. Non-operating items comprised interest income of 0.01B yen and interest expense of 0.13B yen with other minor items netting to a small positive contribution. Extraordinary income of 0.2B yen included gains on asset sales of 0.08B yen, which should be viewed as non-recurring factors contributing approximately 6.7% of pre-tax profit. The gap between ordinary income and net income is primarily explained by the 36.6% effective tax rate rather than extraordinary items. Operating cash flow of 4.5B yen exceeds net income of 3.0B yen, yielding a cash conversion ratio of 1.51x, well above 1.0 and indicating healthy earnings quality with profits converting to cash. The accruals ratio of -2.4% suggests minimal earnings manipulation risk. Core profitability remains strong with operating activities generating sustainable cash flows, though investors should note that net income benefited modestly from non-recurring asset sale gains.
Full-year guidance projects revenue of 61.5B yen (YoY +12.6%), operating income of 11.0B yen (YoY +21.0%), and ordinary income of 11.0B yen (YoY +21.1%). Q2 progress rates stand at 45.5% for revenue, 40.2% for operating income, and 40.9% for ordinary income against full-year targets. Revenue progress is slightly below the standard 50% midpoint expectation for H1, while operating income progress trails more notably at 40.2%, suggesting potential for H2 weighting or cautious guidance. The company revised its forecast during this quarter, though specific revision details are not quantified in the available data. Given the strong YoY profit growth demonstrated in Q2 (+41.3% operating income) versus full-year guidance of +21.0%, management appears to have incorporated conservative assumptions for H2 or expects moderating growth momentum. Progress rates indicate the company is broadly on track but will require H2 acceleration to achieve the full-year operating profit target, particularly given typical seasonality or integration effects from newly acquired subsidiaries.
The company maintains a zero dividend policy with Q2 dividend of 0 yen and full-year dividend forecast of 0 yen, unchanged from the prior year. No dividend revision occurred during the quarter. Payout ratio is 0% as the company retains all earnings for internal investment and growth initiatives. No share buyback activities are disclosed. Total shareholder return ratio remains at 0%, reflecting a strategic priority on reinvestment in business expansion, including M&A activity evidenced by the 3.7B yen subsidiary acquisition during the period. This capital allocation approach aligns with the company's growth investment phase, though the absence of shareholder returns may warrant evaluation as profitability and cash generation strengthen. With operating cash flow robust at 4.5B yen but offset by substantial investing activities, the company appears to prioritize growth over near-term distributions, which is typical for expansion-focused enterprises but should be reassessed as free cash flow generation improves.
Business concentration risk remains elevated as the company operates exclusively in the veterinary hospital single segment, creating vulnerability to sector-specific demand fluctuations, regulatory changes affecting veterinary services, or competitive pressure in the animal healthcare market. Any adverse developments in pet ownership trends, pricing constraints, or regional market dynamics could disproportionately impact consolidated performance without diversification benefits.
Intangible asset and goodwill impairment risk is substantial with goodwill of 18.5B yen (60.7% of equity) and total intangible assets of 19.6B yen comprising 31.4% of total assets. These elevated balances stem from M&A activities and create material downside risk should acquired businesses underperform expectations, requiring periodic impairment testing and potentially resulting in significant non-cash charges that would reduce equity and reported profitability.
Liquidity and working capital risk warrants monitoring with current ratio of 98.7% below the 100% threshold, indicating current liabilities of 13.2B yen slightly exceed current assets of 13.0B yen. While cash of 6.5B yen provides immediate liquidity and operating cash flow generation remains strong, the tight short-term position requires careful management of receivables, payables, and debt maturities. Long-term borrowings increased 37.3% YoY to 17.5B yen, and while interest coverage of 34.03x is healthy, refinancing risk and sensitivity to interest rate increases represent potential pressure points if operating performance softens or credit conditions tighten.
[Industry Position] (Reference - Proprietary Analysis)
The company demonstrates above-median profitability metrics relative to the IT/Telecom industry peer group. Operating margin of 15.8% exceeds the industry median of 14.0% (IQR: 3.8%-18.5%), positioning the company in the upper half of sector peers for operational efficiency. Net profit margin of 10.7% similarly outperforms the industry median of 9.2% (IQR: 1.1%-14.0%), reflecting effective cost control and profit conversion.
Profitability: ROE 9.8% vs. Industry Median 5.6% (IQR: 0.7%-6.2%); Operating Margin 15.8% vs. Industry Median 14.0% (IQR: 3.8%-18.5%); Net Profit Margin 10.7% vs. Industry Median 9.2% (IQR: 1.1%-14.0%)
Financial Health: Equity Ratio 48.9% vs. Industry Median 60.2% (IQR: 50.8%-88.4%), indicating below-median capitalization with higher financial leverage. Current Ratio 0.99x vs. Industry Median 7.74x (IQR: 3.16x-8.09x), substantially below peers and representing a key area of relative weakness requiring attention.
Efficiency: Asset Turnover 0.448x vs. Industry Median 0.35x (IQR: 0.29-0.37), showing superior asset utilization despite capital-intensive operations. Revenue Growth YoY 11.4% underperforms Industry Median 21.0% (IQR: 15.5%-26.8%), suggesting slower top-line expansion relative to sector peers though profitability per revenue unit is higher.
Financial Leverage 2.05x vs. Industry Median 1.55x (IQR: 1.13-1.76) reflects above-average debt utilization to fund growth investments. Cash Conversion Ratio 1.51x exceeds Industry Median 1.22x (IQR: 0.86-1.75), confirming superior earnings quality. CapEx/D&A Ratio 1.28x substantially exceeds Industry Median 0.34x (IQR: 0.24-1.70), indicating aggressive growth capital investment relative to depreciation and peers.
The company's profile combines strong profitability and cash quality with below-peer liquidity and above-peer leverage, consistent with a growth investment phase prioritizing expansion over conservative balance sheet positioning.
※ Industry: IT/Telecom (7 companies), Comparison: 2025-Q2 period, Source: Proprietary analysis
Strong profitability expansion with operating leverage demonstrated through 41.3% operating income growth on 11.4% revenue growth, driven by gross margin improvement to 26.9% and SG&A efficiency gains resulting in 15.8% operating margin (up 3.5pt YoY). This margin trajectory indicates scalability benefits are materializing as the business grows, supported by high-quality cash earnings with operating cash flow at 1.51 times net income.
Growth investment phase evidenced by substantial M&A activity with 3.7B yen subsidiary acquisition and elevated CapEx-to-depreciation ratio of 1.28x, resulting in negative free cash flow of -0.4B yen despite positive operating cash flow. The company maintains zero dividend policy, channeling all retained earnings toward expansion, which is appropriate for the current growth stage but will require demonstration of acceptable returns on invested capital as integration progresses. Goodwill and intangibles totaling 38.1B yen (61% of total assets) represent concentrated acquisition-related assets requiring successful operational integration to avoid impairment risk.
Liquidity positioning warrants monitoring with current ratio of 98.7% below the 100% threshold and cash declining 27.2% YoY to 6.5B yen, though this is offset by strong operating cash generation of 4.5B yen. Long-term debt increased 37.3% to 17.5B yen, elevating financial leverage to 2.05x (above industry median of 1.55x), but interest coverage remains robust at 34.03x providing debt servicing cushion. The balance sheet structure reflects aggressive growth financing through debt while maintaining adequate though not abundant liquidity, requiring continued operational performance to sustain.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.